Krymchantowski AV, et al. - Consecutive migraineurs from a tertiary center who were prescribed sodium divalproate (SD) as monotherapy were studied retrospectively for treatment adherence, tolerability, and effectiveness. Patients were provided alternate doses of 250 mg and 500 mg and were based on the expertise of the treating physician and previous experience with using higher doses and tolerability issues. Among 68 included patients (53 women and 15 men, aged 18-58), 50 reported a decrease in the average headache frequency during baseline from 8.2 to 5.1 headache days/month returning at 2 months (adherence rate 73.5%). Findings support the efficacy of SD in low alternating daily doses is comparable as with higher doses, but it still comes with modest weight gain.